1. Home
  2. KPTI vs EPSN Comparison

KPTI vs EPSN Comparison

Compare KPTI & EPSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • EPSN
  • Stock Information
  • Founded
  • KPTI 2008
  • EPSN 2005
  • Country
  • KPTI United States
  • EPSN Canada
  • Employees
  • KPTI N/A
  • EPSN N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • EPSN Oil & Gas Production
  • Sector
  • KPTI Health Care
  • EPSN Energy
  • Exchange
  • KPTI Nasdaq
  • EPSN Nasdaq
  • Market Cap
  • KPTI 44.5M
  • EPSN 175.3M
  • IPO Year
  • KPTI 2013
  • EPSN N/A
  • Fundamental
  • Price
  • KPTI $4.74
  • EPSN $7.11
  • Analyst Decision
  • KPTI Strong Buy
  • EPSN Strong Buy
  • Analyst Count
  • KPTI 7
  • EPSN 1
  • Target Price
  • KPTI $45.43
  • EPSN $7.00
  • AVG Volume (30 Days)
  • KPTI 146.2K
  • EPSN 314.7K
  • Earning Date
  • KPTI 08-05-2025
  • EPSN 08-12-2025
  • Dividend Yield
  • KPTI N/A
  • EPSN 3.51%
  • EPS Growth
  • KPTI N/A
  • EPSN N/A
  • EPS
  • KPTI N/A
  • EPSN 0.20
  • Revenue
  • KPTI $142,126,000.00
  • EPSN $39,699,172.00
  • Revenue This Year
  • KPTI $2.09
  • EPSN $41.35
  • Revenue Next Year
  • KPTI $12.90
  • EPSN N/A
  • P/E Ratio
  • KPTI N/A
  • EPSN $35.42
  • Revenue Growth
  • KPTI 1.19
  • EPSN 35.21
  • 52 Week Low
  • KPTI $3.51
  • EPSN $4.95
  • 52 Week High
  • KPTI $16.95
  • EPSN $8.50
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 41.48
  • EPSN 39.99
  • Support Level
  • KPTI $4.23
  • EPSN $7.10
  • Resistance Level
  • KPTI $5.14
  • EPSN $7.55
  • Average True Range (ATR)
  • KPTI 0.38
  • EPSN 0.29
  • MACD
  • KPTI 0.04
  • EPSN -0.10
  • Stochastic Oscillator
  • KPTI 24.45
  • EPSN 6.16

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About EPSN Epsilon Energy Ltd. Common Share

Epsilon Energy Ltd is engaged in the acquisition, development, gathering, and production of natural gas and oil reserves. The operating segments of the company include Upstream segment activities including acquisition, development, and production of natural gas reserves on properties within the United States. The Gas Gathering segment partners with two other companies to operate a natural gas gathering system, and the corporate segment activities include corporate listing and governance functions of the corporation. The company generates revenue from the sale of crude oil and natural gas.

Share on Social Networks: